Form 4: Palisade Bio CEO John Finley Reports Stock Transactions

CEO John Finley reports the vesting and settlement of restricted stock units and subsequent acquisition of common stock in Palisade Bio, Inc.

Summary

• On March 11, 2024, John David Finley, CEO, CFO, and Director of Palisade Bio, Inc., acquired 5,558 shares of common stock due to the vesting and settlement of restricted stock units.
• These restricted stock units were granted on June 11, 2023.
• Finley directly owns 96,849 shares of common stock following the transaction.
• He also indirectly owns 777 shares through FCW Investments, LLC, where he has sole investment and voting power.
• An additional 50,025 restricted stock units will vest in equal quarterly installments over the remaining portion of the three-year period from the grant date, subject to continued service.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock transactions related to executive compensation. It doesn't inherently indicate positive or negative sentiment.

Future Outlook

An additional 50,025 restricted stock units will vest in equal quarterly installments over the remaining portion of the three-year period from the grant date, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, like John Finley, and provides transparency into their stock transactions. It's a standard practice for publicly traded companies.

Stakeholder Impact

• The transaction increases the CEO's stake in the company, potentially aligning his interests further with those of shareholders.

Key Dates

Keywords

Palisade Bio, John Finley, Stock, Restricted Stock Units, Beneficial Ownership, Form 4, PALI